Malignant central nervous system tumors among adolescents and young adults (15‐39 years old) in 14 Southern‐Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns

BACKGROUNDUnique features and worse outcomes have been reported for cancers among adolescents and young adults (AYAs; 15‐39 years old). The aim of this study was to explore the mortality and survival patterns of malignant central nervous system (CNS) tumors among AYAs in Southern‐Eastern Europe (SEE) in comparison with the US Surveillance, Epidemiology, and End Results (SEER) program.METHODSMalignant CNS tumors diagnosed in AYAs during the period spanning 1990‐2014 were retrieved from 14 population‐based cancer registries in the SEE region (n = 11,438). Age‐adjusted mortality rates were calculated and survival patterns were evaluated via Kaplan‐Meier curves and Cox regression analyses, and they were compared with respective 1990‐2012 figures from SEER (n = 13,573).RESULTSMortality rates in SEE (range, 11.9‐18.5 deaths per million) were higher overall than the SEER rate (9.4 deaths per million), with decreasing trends in both regions. Survival rates increased during a comparable period (2001‐2009) in SEE and SEER. The 5‐year survival rate was considerably lower in the SEE registries (46%) versus SEER (67%), mainly because of the extremely low rates in Ukraine; this finding was consistent across age groups and diagnostic subtypes. The highest 5‐year survival rates were recorded for ependymomas (76% in SEE and 92% in SEER), and the worst were recorded for glioblastomas and anaplastic astrocytomas (28% in SEE and 37% in SEER). Advancing age, male sex, and rural residency at diagnosis adversely affected outcomes in both regions.CONCLUSIONSDespite definite survival gains over the last years, the considerable outcome disparities between the less affluent SEE region and the United States for AYAs with malignant CNS tumors point to health care delivery inequalities. No considerable prognostic deficits for CNS tumors are evident for AYAs versus children. Cancer 2017;123:4458‐71. © 2017 American Cancer Society.